Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: GVC Down 18% As Chiefs Sell 3 Million Shares

Fri, 08th Mar 2019 10:50

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------Fresnillo, up 1.7%. The Mexican gold miner was tracking spot gold price higher, quoted at USD1,295.07 an ounce, up from USD1,285.30 at the London equities close Thursday. Mid-cap Egyptian miner Centamin was up 1.8%.----------GlaxoSmithKline, up 0.8%. The drugmaker said the Atlas and Flair studies showed that along-acting, injectable two-drug regimen in HIV-1 patients had similar efficacy to a daily three-drug treatment. Both phase three studies assessed a long-acting, injectable combination of cabotegravir and rilpivirine - injected every four weeks - and compared it against a standard of care, daily, three-drug regimen. 48-week data from both studies shows that they met their primary endpoints, showing that the two-drug regimen was not inferior in treating HIV. John Pottage, chief scientific & medical officer Of ViiV Healcare said: "With Flair and Atlas, we now have positive results from two pivotal phase three studies demonstrating that this long-acting, once-monthly injectable regimen has similar efficacy, safety and tolerability to a daily oral three-drug regimen for the treatment of HIV."----------FTSE 100 - LOSERS----------GVC Holdings, down 18% at 563.65 pence. GVC Chair Lee Feldman and Chief Executive Kenneth Alexander sold a significant amount of stock. Alexander sold 2.1 million shares at 666 pence for GBP13.7 million, while Feldman disposed of 900,000 shares at the same price for GBP6.0 million. Alexander said: "We have both held large personal shareholdings in GVC for a long time and continue to do so. Both of us remain fully committed to GVC and, whilst I continue to have the support of our shareholders, I'm here for the long term and at the very least I have a current plan that will take three plus years to accomplish."----------FTSE 250 - WINNERS----------SIG, up 9.1%. The building products supplier reported a drop in annual revenue, though it swung to a pretax profit. SIG's statutory revenue fell to GBP2.74 billion in 2018, from GBP2.88 billion in 2017, but it returned to pretax profit, posting GBP28.5 million from a GBP54.7 million loss a year prior. On an underlying basis, revenue fell 1.2% to GBP2.68 billion, with like-for-like sales down 2.1%. SIG's underlying pretax profit was up 8.5% to GBP75.3 million. SIG is paying a 2.5p final dividend, meaning the total for 2018 is unchanged from the year before at 3.75p. The company said its transformation strategy is now beginning to take shape, with the second half of 2018 seeing "significant" progress.----------Bodycote, up 7.2%. The thermal processing firm reported solid revenue and profit growth for 2018, with all of its divisions managing to report revenue improvement. The firm's statutory pretax profit climbed to GBP132.2 million from GBP117.0 million, with the headline figure up 12% to GBP136.4 million. Bodycote's revenue rose 5.6%, and 6.7% at constant currency rates, to GBP728.6 million. The company will pay a final dividend of 13.2p, taking the 2018 total to 19.0p from 17.4p a year before. On top of that, it also will pay a special dividend of 20p, having returned a special payout of 25p in 2017. Bodycote had a strong year, the company said, and it enters 2019 "well positioned".----------FTSE 250 - LOSERS----------Saga, down 9.0%. JPMorgan downgraded Saga to Underweight from Neutral, saying a weak balance sheet, alongside heightened insurance industry competition, could lead to concerns about the over 50s travel and insurance services provider's dividend. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Panthera Resources, up 20%. The miner reported positive developments from an investee, including a "significant" acquisition. Panthera has a 17% stake in Anglo Saxony Mining, a European explorer and developer with a flagship tin project in Tellerhauser, Germany. ASM's purchase is the Gottesberg tin deposit, 28 kilometres to the west of Tellerhauser, paid with both cash and shares. Gottesberg has a total resource of 42.1 million tonnes of ore at a grade of 0.27% tin, suggesting 113,000 tonnes of the commodity. Combining Gottesberg and Tellerhauser's resources, ASM now has a resource of 217,000 ounces of tin, which Panthera said is among the largest in the world. ----------Debenhams, up 13%. The troubled department store chain said it is "disappointed" that Sports Direct International has decided to requisition a general meeting to appoint Sports Direct boss Mike Ashley to the Debenhams board and remove all but one current board member. Debenhams added it has been engaging with both Sports Direct and other stakeholders regarding options to restructure the company's balance sheet. Sports Direct late Thursday said Founder & Chief Executive Ashley is seeking appointment to Debehmans board of directors. Ashley is aiming to be appointed to an executive role to focus on Debenhams business, including building a strong board and management team. Furthermore, Sports Direct is seeking to oust all Debenhams' board members with the exception of Rachel Osborne, who became a director in September 2018. If appointed, Ashley would step down from his current roles as a director & CEO of Sports Direct, which was down 0.5%.----------OTHER MAIN MARKET AND AIM - LOSERS----------Goals Soccer Centres, down 28%. The five-a-side football pitch operator said it expects 2018 results to be "materially below" expectations following discovery of accounting errors. Goals explained that results for the full year are now expected to be "materially below expectations" and delayed from their originally planned reporting date of March 12. This follows the firm - alongside its auditors - having to resolve some "accounting errors". Goals emphasised that the "majority" of these expected accounting adjustments are "non-cash" in nature. Despite this, the changes would mean that the firm will have "exceeded one of its banking covenants". Goals is currently discussing with the bank to agree new, renegotiated facilities. For the first two months of 2019, Goals reported trading had been "strong" with an increases in like-for-like sales on the prior year in both the UK and US.----------

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.